

12-1-2022

## **Expression and localization of NRF2/Keap1 signalling pathway genes in mouse preimplantation embryos exposed to free fatty acids.**

Grace Dionne  
*Western University*

Michele D. Calder  
*University of Western Ontario, mcalder@uwo.ca*

Dean H Betts  
*Western University, dean.betts@schulich.uwo.ca*

Basim Abu Rafea  
*Western University*

Andrew J Watson  
*Western University, awatson@uwo.ca*

Follow this and additional works at: <https://ir.lib.uwo.ca/obsgynpub>



Part of the [Obstetrics and Gynecology Commons](#)

---

### **Citation of this paper:**

Dionne, Grace; Calder, Michele D.; Betts, Dean H; Rafea, Basim Abu; and Watson, Andrew J, "Expression and localization of NRF2/Keap1 signalling pathway genes in mouse preimplantation embryos exposed to free fatty acids." (2022). *Obstetrics & Gynaecology Publications*. 124.  
<https://ir.lib.uwo.ca/obsgynpub/124>

1 **For submission to Gene Expression Patterns- revised clean version**

2

3 **Expression and Localization of NRF2/Keap1 signaling pathway genes in mouse**  
4 **preimplantation embryos exposed to free fatty acids**

5

6 Grace Dionne<sup>1,2,3</sup>, Michele Calder<sup>1,2,3</sup>, Dean H. Betts<sup>1,2,3</sup>, Basim Abu Rafea<sup>1,3</sup>, and Andrew J.  
7 Watson<sup>1,2,3</sup>

8 <sup>1</sup>Department of Obstetrics and Gynaecology, <sup>2</sup>Department of Physiology and Pharmacology,  
9 University of Western Ontario, London ON, Canada, N6A 5C1; <sup>3</sup>The Children's Health  
10 Research Institute – Lawson Health Research Institute, London ON, Canada, N6C 2R5

11

12 Grant Support: Canadian Institutes of Health Research project grant

13

14 Correspondence: Dr. Andrew J. Watson, Obstetrics and Gynaecology & Physiology and  
15 Pharmacology, Room 257, Medical Sciences Building, University of Western Ontario, 1151  
16 Richmond St, London ON, Canada, N6A 5C1; Phone: (519) 661-2111 x89132; Fax: (519) 661-  
17 3721; Email: [awatson@uwo.ca](mailto:awatson@uwo.ca)

18

19 Running title: Free Fatty Acids and NRF2/KEAP1 in Mouse Embryos

20

21 Key words: preimplantation embryo, obesity, infertility, palmitate, NRF2

22

23 **Abstract**

24           Obese women experience greater incidence of infertility, with reproductive tracts exposing  
25 preimplantation embryos to elevated free fatty acids (FFA) such as palmitic acid (PA) and oleic  
26 acid (OA). PA treatment impairs mouse preimplantation development *in vitro*, while OA co-  
27 treatment rescues blastocyst development of PA treated embryos. In the present study, we  
28 investigated the effects of PA and OA treatment on NRF2/ Keap1 localization, and relative  
29 antioxidant enzyme (Glutathione peroxidase; *Gpx1*, Catalase; *Cat*, Superoxide dismutase; *Sod1*  
30 and  $\gamma$ -Glutamylcysteine ligase catalytic unit; *Gclc*) mRNA levels, during *in vitro* mouse  
31 preimplantation embryo development. Female mice were superovulated, mated, and embryos  
32 cultured in the presence of bovine Serum albumin (BSA) control or PA, or OA, alone (each at 100  
33  $\mu$ M) or PA+OA combined (each at 100  $\mu$ M) treatment. NRF2 displayed nuclear localization at all  
34 developmental stages, whereas Keap1 primarily displayed cytoplasmic localization throughout  
35 control mouse preimplantation development *in vitro*. Relative transcript levels of *Nrf2*, *Keap1*, and  
36 downstream antioxidants significantly increased throughout control mouse preimplantation  
37 development *in vitro*. PA treatment significantly decreased blastocyst development and the levels  
38 of nuclear NRF2, while OA and PA+OA treatments did not. PA and OA treatments did not impact  
39 relative mRNA levels of *Nrf2*, *Keap1*, *Gpx1*, *Cat*, *Sod1* or *Gclc*. Our outcomes demonstrate that  
40 cultured mouse embryos display nuclear NRF2, but that PA treatment reduces nuclear NRF2 and  
41 thus likely impacts NRF2/KEAP1 stress response mechanisms. Further studies should investigate  
42 whether free fatty acid effects on NRF2/KEAP1 contribute to the reduced fertility displayed by  
43 obese patients.

## 44 1. Introduction

45 Infertility may impact up to 1 in 6 couples worldwide (Boivin et al., 2007), and its  
46 prevalence is driving increased demand for assisted reproductive technologies (ARTs) to improve  
47 pregnancy outcomes (Sunderam et al., 2018; Chambers et al., 2021). Obese women experience  
48 higher incidence of infertility than patients with lower body mass index (Talmor & Dunphy, 2015).  
49 In 2019, 53.4% of Canadian women were either overweight or obese (Statistics Canada, 2020).  
50 The effects of maternal obesity on reproductive health include irregular menstruation, polycystic  
51 ovarian syndrome, ovulatory dysfunction, and impaired oocyte and preimplantation embryo  
52 development (ASRM, 2015; Talmor & Dunphy, 2015; Broughton & Moley, 2017). When obese  
53 women conceive, there is a higher risk of miscarriage, gestational diabetes and preeclampsia,  
54 preterm delivery, large and small for gestational age infants, and birth defects (ASRM, 2015).  
55 Obesity alters the reproductive tract environment, but while the mechanisms linking obesity to  
56 female reproductive health are not fully understood, some of the negative consequences are likely  
57 due to lipotoxicity (Broughton & Moley, 2017).

58 Preimplantation embryo development is the free-living period of development between  
59 oocyte fertilization and blastocyst implantation in the uterus and is commonly targeted during  
60 application of assisted reproductive technologies (ARTs) (Watson & Barcroft, 2001; Bell et al.,  
61 2008). Human and mouse embryos exhibit several morphological similarities during  
62 preimplantation development (Wamaitha & Niakan, 2018). Following insemination, as the zygote  
63 proceeds through cleavage divisions, there are waves of transcriptional activity throughout  
64 preimplantation development as the embryonic genome assumes increasing control over  
65 development (Hamatani et al., 2004; Bell et al., 2008; Wamaitha & Niakan, 2018). At the 8-cell  
66 stage, mouse blastomeres undergo compaction to form the morula, and cell lineage specification  
67 mechanisms promote inner cells into the inner cell mass (ICM; future embryonic tissue) and outer  
68 cells into the trophectoderm (TE; future extraembryonic tissue) (Chazaud & Yamanaka, 2016;  
69 Wamaitha & Niakan, 2018). Blastocyst formation, as characterized by the formation of a fluid-  
70 filled cavity then ensues and is a critical determinant of developmental competence required for  
71 initiation of pregnancy (Watson & Barcroft, 2001).

72 Preimplantation embryos are equipped to respond adaptively to their external environment,  
73 whether it be the reproductive tract, *in vivo* or the culture environment *in vitro* by activating several  
74 mechanisms including endoplasmic reticulum stress pathways (Abraham et al., 2012; Lin et al.,

75 2019) and antioxidant pathways (Harvey et al., 1995) regulated by numerous growth factor and  
76 cytokine regulatory circuits. Obesity is associated with lipotoxicity—defined by the accumulation  
77 of lipids in non-adipose tissue which can induce inflammation and cellular stress (Mota et al.,  
78 2016). Obesity and elevated free fatty acids (FFAs) can increase ER stress, mitochondrial  
79 dysfunction, reactive oxygen species (ROS) production and apoptosis (Furukawa et al., 2004; Wei  
80 et al., 2006; Mota et al., 2016). Elevated ROS in the mouse and bovine embryo can lead to  
81 developmental arrest (Guerin et al., 2001; Favetta et al., 2007).

82 Palmitic acid (PA) and oleic acid (OA) are the most abundant FFAs in human circulation  
83 and the mouse reproductive tract (Jungheim et al., 2011; Abdelmagid et al., 2015; Yousif et al.,  
84 2020). Excessive intracellular PA metabolism is linked to negative outcomes including ER stress,  
85 apoptosis, and insulin resistance, through activation of diacylglycerol and ceramide synthetic  
86 pathways (Palomer et al., 2018). High PA content in bovine follicular fluid and culture media is  
87 associated with poor oocyte morphology, reduced fertilization, poorer cleavage, and blastocyst  
88 development (Leroy et al., 2005; Sinclair et al., 2008; Aardema et al., 2011). In contrast,  
89 intracellular OA metabolism induces triacylglycerol formation, which promotes storage in lipid  
90 droplets instead of their metabolism into lipotoxic compounds such as diacylglycerol or ceramides  
91 (Aardema et al., 2011; Palomer et al., 2018; Yousif et al., 2020). High OA content in follicular  
92 fluid and culture media is associated with higher oocyte quality, better fertilization rates and  
93 improved bovine and mouse preimplantation development (Aardema et al., 2011; Yousif et al.,  
94 2020). However, it is clear there is an upper limit to this benefit of storing lipid in droplets as  
95 higher levels are detrimental to porcine and bovine preimplantation development (Abe et al., 1999;  
96 Kikuchi et al., 2002). We have reported that treatment with 100  $\mu$ M PA *in vitro* significantly  
97 reduces development of mouse embryos to the blastocyst stage and increases ER stress pathway  
98 mRNAs, while co-treatment with OA reverses the negative effects of PA exposure (Yousif et al.,  
99 2020).

100 Here we investigate the NF-E2 p45-related factor 2 (NRF2)/Kelch-like ECH associated  
101 protein 1 (KEAP1) signalling pathway to advance our understanding of PA and OA effects during  
102 mouse preimplantation development. NRF2 is a nuclear transcription factor and coordinator of  
103 cytoprotective responses, including antioxidant pathways (Suzuki & Yamamoto, 2015; Huang et  
104 al., 2015). NRF2 is tightly regulated at the transcriptional, translational, and post-translational  
105 levels, but is primarily controlled via proteasomal degradation (Huang et al., 2015; Tonelli et al.,

106 2018). Normally, KEAP1, the primary regulatory protein of NRF2, binds to NRF2 and directs  
107 ubiquitin substrate binding (Cullinan et al., 2004). Under cellular stress conditions, electrophiles  
108 alter the interaction between NRF2 and KEAP1 (Huang et al., 2015). NRF2 translocates to the  
109 nucleus and binds to antioxidant response elements (AREs) in the promoters of target genes  
110 (Jaiswal, 2004; Suzuki & Yamamoto, 2015). Among these targets are catalase (CAT), superoxide  
111 dismutase (SOD1), glutathione peroxidase (GPX1) and  $\gamma$ -Glutamylcysteine ligase catalytic unit  
112 (GCLC) which play critical roles in metabolizing harmful oxidants from cellular environment  
113 (Thimmulappa et al., 2002; Lee et al., 2003; Liu et al., 2017). These antioxidant mRNAs are  
114 detectable in early mouse embryos (Harvey et al., 1995; Calder et al., 2011). NRF2/KEAP1  
115 signalling is widely implicated in health and disease, protecting from oxidative stress and  
116 xenobiotics, including critical role(s) in development (Kensler et al., 2007; Dong et al., 2008;  
117 Huang et al., 2015; Sant et al., 2017). Activation of NRF2 is proposed as treatment for some  
118 diseases including obesity (Elrashidy et al, 2020; Zhu et al., 2020), however caution should be  
119 taken as activation may improve resistance of cancer cells (Sporn & Liby, 2012; Huang et al.,  
120 2015).

121 The relationships between FFAs, stress response pathways, and preimplantation embryo  
122 development are complex. To eventually address fertility challenges faced by obese women, it is  
123 necessary to define how obesity impacts reproductive health, including the impacts of abundant  
124 FFAs like PA and OA. Therefore, we have investigated a possible link between FFA treatment  
125 and NRF2/KEAP1 signalling during *in vitro* mouse preimplantation embryo development. Our  
126 outcomes demonstrate that PA treatment reduces nuclear NRF2 and thus likely impacts  
127 NRF2/KEAP1 stress response mechanisms.


## 128 **2.Results**

### 129 **2.1 Immunolocalization of NRF2 and KEAP1 during mouse preimplantation development** 130 *in vitro*.

131 We first defined the NRF2/KEAP1 immunolocalization patterns throughout BSA control  
132 (no PA or OA treatment) mouse preimplantation development *in vitro*. NRF2 immunofluorescent  
133 protein labelling was consistently detected in the nuclei of mouse preimplantation embryos from  
134 the 1-cell zygote to the blastocyst stage (**Figure 1A & B**). Blastocysts displayed a significantly

135 higher percentage of NRF2 positive nuclei ( $89.76\pm 1.06\%$ ) compared to 4-cell embryos  
 136 ( $72.61\pm 4.02\%$ ;  $p<0.05$ ) and 1-cell zygotes ( $67.92\pm 5.80\%$ ;  $p<0.01$ ). The immunolocalization  
 137 pattern of NRF2 is shown in representative confocal images (**Figure 1B**). NRF2 protein  
 138 immunolocalization was also detected in the cytoplasm of blastomeres from all preimplantation  
 139 developmental stages, though this was not quantified.


140  
 141  
 142  
 143  
 144  
 145  
 146  
 147  
 148  
 149  
 150  
 151



152 **Figure 1. (A) Mean positive NRF2 nuclei ( $\% \pm \text{SEM}$ ) at each major stage of preimplantation**  
 153 **embryo development.** Nuclear NRF2 localization frequency increased throughout  
 154 preimplantation embryo development, peaking at the blastocyst stage. Percentage of NRF2  
 155 positive nuclei was significantly higher at the blastocyst ( $89.76\pm 1.06\%$ ) stage compared with the  
 156 1-cell ( $67.92\pm 5.80\%$ ) and 4-cell stages ( $72.61\pm 4.02\%$ ), per one-way ANOVA with Tukey's post-

157 hoc test (\*p<0.05, \*\*p<0.01, \*\*\*p<0.001). N=3 experimental replicates (embryo collections) with  
 158 a total of n=30-40 embryos measured per treatment group. **(B) Immunofluorescence images show**  
 159 **NRF2, F-actin and DAPI localization at each stage of preimplantation embryo development.**  
 160 Nuclear NRF2 localization is evident at the 1-cell, 2-cell, 4-cell, 8-cell, morula, and blastocyst  
 161 stages, assessed via overlap between NRF2 and DAPI. Images via Zeiss LSM 800 confocal  
 162 microscope. Scale bar = 50µm.

163 KEAP1 immunofluorescent localization was observed in the cytoplasm in all stages of  
 164 preimplantation embryo development (**Figure 2A & B**). The mean percentage of KEAP1 positive  
 165 cells was consistently above 90% in all embryo stages and did not differ significantly between the  
 166 1-cell, 2-cell, 4-cell, 8-cell, and morula groups. Thought interestingly, the percentage of KEAP1  
 167 positive cells was significantly lower at the blastocyst stage (91.60±1.00%) compared with the 2-  
 168 cell stage (97.85±1.50%). KEAP1 was immunolocalized to a small percentage of nuclei in all  
 169 developmental stages except the 1-cell, though this was not precisely quantified. KEAP1  
 170 immunofluorescence also included cytoplasmic foci, and a subcortical cytoplasmic halo in each  
 171 blastomere at each embryo stage (**Figure 2B**).



181 **Figure 2. (A) Mean positive KEAP1 cells (%±SEM) at each stage of preimplantation embryo**  
182 **development.** Cytosolic KEAP1 was consistently present throughout all stages of preimplantation  
183 embryo development N=3 experimental replicates (embryo collections) with a total of n=30-40  
184 embryos measured per treatment group. Percentage of KEAP1 positive cells was significantly  
185 lower at the blastocyst stage (91.60±1.00%) compared with the 2-cell stage (97.85±1.50%). Data  
186 were analyzed using one-way ANOVA with Tukey's post-hoc test to determine significance  
187 (\*p<0.05). **(B) Immunofluorescence images show KEAP1, F-actin and DAPI localization at**  
188 **each major stage of preimplantation embryo development.** Cytosolic KEAP1 presence is  
189 evident at the 1-cell, 2-cell, 4-cell, 8-cell, morula, and blastocyst stages. Scale bar = 50µm


190

## 191 **2.2 Relative mRNA abundance of *Nrf2*, *Keap1*, and downstream antioxidants during mouse** 192 ***preimplantation development in vitro***

193 We next assessed the relative abundance of NRF2/KEAP1 mRNA transcripts and selected  
194 downstream antioxidant mRNA transcripts during mouse preimplantation development *in vitro*.  
195 The relative abundance of *Nrf2* mRNA (compared to exogenously supplied luciferase mRNA; see  
196 methods) was significantly higher in blastocysts compared to the 1-cell to 8-cell stages (all p<0.01;  
197 **Figure 3A**), while the morula stage was intermediate. The relative mRNA abundance of *Keap1*  
198 was significantly higher in blastocysts compared to the 1-8 cell stages (all p<0.03; **Figure 3B**),  
199 while the morula stage did not differ from the other groups. The relative mRNA abundance of  
200 *Gpx1* significantly varied between blastocysts compared with 1-cell stage (p<0.03; **Figure 3C**),  
201 while the other stages were intermediate. The relative mRNA abundance of *Cat* was significantly  
202 higher in blastocysts compared with all other developmental stages (all p<0.005) and showed a  
203 100-fold increase from the 1-cell stage (**Figure 3D**). The relative mRNA abundance of *Sod1* was  
204 significantly different between the blastocyst group compared with 2-cell stage only (p<0.02;  
205 **Figure 3E**). The relative mRNA abundance of *Gclc* was not significantly different amongst  
206 embryo stages (p>0.19; **Figure 3F**).

207

208



225 **Figure 3. Mean relative mRNA abundance (±SEM) of (A) *Nrf2*, (B) *Keap1*, (C) *Gpx1*,**  
 226 **(D) *Cat*, (E) *Sod1* and (F) *Gclc* at each stage of preimplantation embryo development. Relative**  
 227 **transcript abundances (compared to exogenously supplied luciferase mRNA; see methods) of *Nrf2*,**  
 228 ***Keap1*, *Gpx1*, *Cat*, *Sod1* and *Gclc* increase throughout mouse preimplantation embryo**

229 development. **A.** The relative abundance of *Nrf2* mRNA (compared to exogenously supplied  
230 luciferase mRNA; see methods) was significantly higher in blastocysts compared to the 1-cell to  
231 8-cell stages (all  $p < 0.01$ ), while the morula stage was intermediate. **B.** *Keap1* relative abundance  
232 was significantly higher in blastocysts compared to the 1-8 cell stages (all  $p < 0.03$ ), while the  
233 morula stage did not differ from the other groups. **C.** *Gpx1* relative significantly varied between  
234 blastocysts compared with 1-cell stage ( $p < 0.03$ ), while the other stages were intermediate. **D.** *Cat*  
235 relative abundance was significantly higher in blastocysts compared with all other developmental  
236 stages (all  $p < 0.005$ ) and showed a 100-fold increase from the 1-cell stage. **E.** *Sod1* relative  
237 abundance was significantly different between the blastocyst group compared with 2-cell stage  
238 only ( $p < 0.02$ ). **F.** *Gclc* was not significantly different amongst embryo stages ( $p > 0.19$ ). Relative  
239 transcript abundance in each group was compared using one-way ANOVA with Tukey's post-hoc  
240 test for *Keap1*, *Gclc* and *Cat*, Kruskal-Wallis non-parametric test for *Nrf2*, *Sod1* and *Gpx1* with  
241 Dunn's post-hoc test. (a,b Bars with different superscripts are significantly different, (N=3  
242 experimental replicates each consisting of RNA extracted pools of 20 embryos for each stage; for  
243 all analyses).

244


### 245 **2.3 Effects of PA and OA treatment on NRF2, KEAP1 protein localization during mouse** 246 **preimplantation embryo development, *in vitro***

247 After examining untreated control *in vitro* preimplantation embryo development, we  
248 proceeded with determining the effects of PA and OA exposure on NRF2 and KEAP1  
249 immunolocalization in a time course including 18, 24 and 48 hrs of PA, OA, and PA and OA  
250 combined treatment.

#### 251 **2.3.1 Localization of NRF2, KEAP1 protein after 18-hour culture with FFAs**

252 After 18 hours of culture in the presence of BSA control, 100 $\mu$ M PA, 100 $\mu$ M OA, or  
253 100 $\mu$ M PA+OA, most embryos, including those exposed to PA, 2-cell stage embryos proceeded  
254 to the 4-cell or 8-cell stage. No obvious impact of PA treatment on developmental stage was  
255 observed at this time-point (data not shown). After 18 hours of culture, nuclear NRF2  
256 immunolocalization was present in embryos from all four treatment groups. The mean percentage

257 of NRF2-positive nuclei was significantly lower in PA-treated embryos ( $58.07 \pm 4.19\%$ ) compared  
 258 with PA+OA treated embryos ( $73.16 \pm 3.56\%$ ;  $p < 0.05$ ; **Figure 4A & B**). KEAP1  
 259 immunolocalization was detected in the cytoplasm of all treatment groups at the 18-hour time-  
 260 point, but the percentage of KEAP1-positive cells did not differ significantly across groups. The  
 261 percentage of KEAP1-immunopositive cells was above 95% in all four treatment groups (**Figure**  
 262 **4C & D**). KEAP1 immunofluorescence was also observed to include a consistent subcortical  
 263 cellular halo distribution in all treatment groups.



278 **Figure 4. (A) Mean positive NRF2 nuclei (%±SEM) in embryos following 18-hour culture in**  
279 **BSA, PA, OA, or PA+OA treatment conditions.** Treatment with 100 μM PA significantly  
280 decreased the percentage of NRF2-positive nuclei per embryo (58.07±4.19%) compared with the  
281 PA+OA group (73.16±3.56%, \*p<0.05). N=3 experimental replicates (embryo collections) with a  
282 total of n=30-40 embryos measured per treatment group. **(B) Immunofluorescence images show**  
283 **NRF2, F-actin and DAPI localization following 18-hour culture in BSA, PA, OA, or PA+OA**  
284 **treatment conditions.** Nuclear NRF2 localization is evident in all treatment groups at 18 hours of  
285 culture. **(C) Mean positive KEAP1 cells (%±SEM) in embryos following 18-hour culture in**  
286 **BSA, PA, OA, or PA+OA treatment conditions.** Inclusion of FFA in embryo culture media did  
287 not impact KEAP1 positive cells per embryo in the BSA control (99.12±0.51%), PA  
288 (99.09±0.66%), OA (97.18±0.95%) and PA+OA (97.75±0.98%) groups. **(D)**  
289 **Immunofluorescence images showing KEAP1, F-actin and DAPI localization following 18-**  
290 **hour culture in BSA, PA, OA, or PA+OA treatment conditions.** Cytosolic KEAP1 localization  
291 is evident in all treatment groups at 18 hours of culture. N=3 experimental replicates (embryo  
292 collections) with a total of n=30-40 embryos measured per treatment group. Scale bars equal  
293 50μm.

294


### 295 **2.3.2 Localization of NRF2, KEAP1 after 24-hour culture with FFAs**

296 NRF2 immunolocalization was present in the nuclei of embryos from BSA control, 100  
297 μM PA, 100 μM OA, and 100 μM PA+OA after 24 hours of culture, but the frequency of NRF2-  
298 positive nuclei did not differ significantly between any treatment groups (**Figure 5A & B**).  
299 Cytoplasmic KEAP1 localization was observed in all treatment groups after 24 hours of culture,  
300 and the mean percentage of KEAP1-positive cells did not differ significantly, while remaining  
301 high (>90%) in all treatment groups (**Figure 5C & D**).

302

303

304



322 **Figure 5. (A) Mean positive NRF2 nuclei (%±SEM) in embryos following 24-hour culture**  
 323 **in BSA, PA, OA or PAOA treatment conditions.** Inclusion of FFA in embryo culture media  
 324 did not significantly impact the mean percentage of NRF2 positive nuclei per embryo in the BSA  
 325 (66.48±4.24%), PA (73.93±3.70%), OA (74.03±3.45%) and PA+OA (73.14±3.11%) groups.  
 326 N=3 experimental replicates (embryo collections) with a total of n=30-40 embryos measured per  
 327 treatment group.

328 **(B) Immunofluorescence images showing NRF2, F-actin and DAPI localization following**  
329 **24- hour culture in BSA, PA, OA or PAOA treatment conditions.** Nuclear NRF2 localization  
330 is evident in all treatment groups at 24 hours of culture. **(C) Mean positive KEAP1 cells**  
331 **(%±SEM) in embryos following 24-hour culture in BSA, PA, OA or PAOA treatment**  
332 **conditions.** Inclusion of FFA in embryo culture media did not significantly impact the mean  
333 percentage of KEAP1 positive cells per embryo in the BSA (98.21±0.81%), PA (97.89±0.83%),  
334 OA (98.51±0.66%) and PA+OA (98.65±0.69%) groups. N=3 experimental replicates (embryo  
335 collections) with a total of n=30-40 embryos measured per treatment group. **(D)**  
336 **Immunofluorescence images showing KEAP1, F-actin and DAPI localization following 24-**  
337 **hour culture in BSA, PA, OA or PAOA treatment conditions.** Cytosolic KEAP1 localization  
338 is evident in all treatment groups at 24 hours of culture. Scale bars equal 50µm.

339

### 340 **2.3.3 Localization of NRF2, KEAP1 after 48-hour culture with FFAs**





341 NRF2 localization was present in the nuclei of embryos from BSA control, 100 µM PA,  
342 100 µM OA, and 100 µM PA+OA groups after 48 hours of culture. PA exposure significantly  
343 decreased the frequency of NRF2-positive nuclei (73.62±2.34%) compared with BSA control  
344 (90.07±1.15%), OA (87.65±1.60%), and PA+OA (90.50±1.40%) treatment groups (p<0.0001;  
345 **Figure 6A & B**). NRF2 immunofluorescence was consistently detected in the cytoplasm. KEAP1  
346 displayed consistent cytoplasmic localization in embryos from all treatment groups after 48 hours  
347 of culture. OA treatment alone significantly decreased the frequency of KEAP1-positive cells  
348 (53.31±2.79%) compared with the BSA control (71.97±2.41%), PA (76.95±2.09%) and PA+OA  
349 (86.38±1.50%) groups (p<0.0001; **Figure 6C & D**).

350

351

352

353  
 354  
 355  
 356  
 357  
 358  
 359  
 360  
 361  
 362  
 363  
 364  
 365  
 366  
 367  
 368  
 369  
 370  
 371  
 372  
 373  
 374  
 375  
 376  
 377  
 378  
 379  
 380  
 381  
 382




383 **Figure 6. (A) Mean positive NRF2 nuclei (%±SEM) in embryos following 48-hour culture**  
384 **in BSA, PA, OA or PAOA treatment conditions.** Inclusion of 100 µM PA in embryo culture  
385 media significantly decreased the percentage of positive NRF2 nuclei per embryo (73.62±2.35%)  
386 compared with BSA control (90.07±1.15%), OA (87.65±1.60%), and PA+OA (90.50±1.41%)  
387 treatments (\*\*\*\*p<0.0001). N=3 experimental replicates (embryo collections) with a total of  
388 n=30-40 embryos measured per treatment group. **(B) Immunofluorescence images showing**  
389 **NRF2, F-actin and DAPI localization following 48- hour culture in BSA, PA, OA or PAOA**  
390 **treatment conditions.** Nuclear NRF2 localization is evident in all treatment groups. **(C) Mean**  
391 **positive KEAP1 cells (%±SEM) in embryos following 48-hour culture in BSA, PA, OA or**  
392 **PAOA treatment conditions.** Inclusion of 100 µM OA in embryo culture media significantly  
393 decreased the percentage of KEAP1 positive cells per embryo (53.31±2.79%) compared with the  
394 BSA (71.97±2.41%), PA (76.95±2.09%), and PA+OA (86.38±1.50%) treatment groups  
395 (\*p<0.05, \*\*\*\*p<0.0001). N=3 experimental replicates (embryo collections) with a total of  
396 n=30-40 embryos measured per treatment group. **(D) Immunofluorescence images showing**  
397 **KEAP1, F-actin and DAPI localization following 48- hour culture in BSA, PA, OA or**  
398 **PAOA treatment conditions.** Cytosolic KEAP1 localization is evident in all treatment groups at  
399 48 hours of culture. Scale bars equal 50µm.

400

#### 401 **2.4 Effects of FFA treatment on relative NRF2, KEAP1 and antioxidant mRNA levels**

402 Lastly, we assessed the effects of PA and OA treatment on the relative abundance of NRF2,  
403 KEAP1 and the selected antioxidant enzyme mRNAs (*Gpx1*, *Cat*, *Sod1* and *Gclc*). The relative  
404 abundance of *Nrf2* mRNA tended to be lower in the PA group (p>0.0535; **Figure 7A**). The relative  
405 mRNA abundance of *Keap1* was not different among treatment groups (p>0.22; **Figure 7B**). The  
406 relative mRNA abundance of *Gpx1* was not different among treatment groups (p>0.24; **Figure**  
407 **7C**). The relative mRNA abundance of *Cat* tended to be lower in the PA group (p>0.11; **Figure**  
408 **7D**). The relative mRNA abundance of *Sod1* was not different among treatment groups (p>0.85;  
409 **Figure 7E**). The relative mRNA abundance of *Gclc* was not significantly different among  
410 treatments (p>0.56; **Figure 7F**).

411



427 **Figure 7.** Mean relative mRNA abundance ( $\pm$ SEM) of (A) *Nrf2*, (B) *Keap1*, (C) *Gpx1*, (D) *Cat*,  
 428 (E) *Sod1* and (F) *Gclc* after 48h of treatment with BSA, PA, OA, or PA + OA. (A) Relative  
 429 *Nrf2* abundance tended to be lower in the PA group,  $p > 0.0535$ . (B) Relative *Keap1* abundance was  
 430 not different among treatment groups,  $p > 0.22$ . (C) Relative *Gpx1* abundance was not different  
 431 among treatment groups,  $p > 0.24$ . (D) Relative *Cat* abundance tended to be lower in the PA group,  
 432  $p > 0.11$ . (E) Relative *Sod1* abundance was not different among treatment groups,  $p > 0.85$ . (F)

433 Relative *Gclc* abundance was not different among treatment groups,  $p > 0.56$ . Relative transcript  
434 abundance in each group was compared using one-way ANOVA with Tukey's post-hoc test for  
435 *Nrf2*, *Keap1*, *Gpx1* and *Cat*, Kruskal-Wallis non-parametric test for *Sod1* and *Gclc* with Dunn's  
436 post-hoc test. (a,b Bars with different superscripts are significantly different). N=4 for *Keap1* and  
437 *Gclc*, N=5 for *Nrf2*, *Gpx1*, *Sod1* and *Cat*.

### 438 3. Discussion

439 NRF2/KEAP1 signalling has been researched extensively as one of the dominant stress  
440 response pathways in eukaryotic cells (Huang et al., 2015), and dysregulation is coincident with  
441 several diseases (Kensler et al., 2007; Cuadrado et al., 2019). NRF2 is activated by oxidative and  
442 ER stresses which increases NRF2 translocation into the nucleus (Cullinan et al., 2003; Kensler et  
443 al., 2007). NRF2 exerts effects on downstream stress response pathways in many cell systems,  
444 including antioxidant genes *Gpx1*, *Cat*, *Sod1* and *Gclc* (Thimmulappa et al., 2002; Lee et al., 2003;  
445 Liu et al., 2017). However, few studies have considered NRF2/KEAP1 signalling during  
446 mammalian preimplantation development in bovine, porcine and mouse species (Amin et al., 2014;  
447 Lin et al., 2018; Kim et al., 2019).

448 One of the somewhat surprising outcomes we observed was that even under the best  
449 possible control mouse embryo culture conditions, NRF2 was consistently detected in the nuclei  
450 at all mouse preimplantation stages, and the frequency of NRF2-positive nuclei increased as  
451 preimplantation development advanced, *in vitro*. Nuclear and cytoplasmic staining of NRF2 was  
452 noted in an earlier study of mouse embryos (Lin et al., 2018). However, studies in other tissues  
453 suggest that NRF2 is primarily nuclear, required for basal as well as stress-mediated transcription  
454 of its target genes (Nguyen et al., 2005). Embryo culture itself is a known stressor, which may  
455 increase nuclear NRF2 localization (Amin et al., 2014). Amin *et al.* (2014) demonstrated that  
456 embryo culture under 20% O<sub>2</sub> elevated *Nrf2* and antioxidant enzyme mRNA levels in bovine  
457 embryos. We routinely employ a low O<sub>2</sub> (5%O<sub>2</sub>/5%CO<sub>2</sub>/90%N<sub>2</sub>) culture atmosphere for all  
458 preimplantation mouse development culture studies as it has been demonstrated in many studies  
459 to improve preimplantation development *in vitro* in several species (Meintjes et al., 2009; Wale &  
460 Gardner, 2012; Amin et al., 2014; Herbemont et al., 2021) and reduce mis-regulation of embryonic

461 gene transcripts (Rinaudo et al., 2006). Therefore, nuclear NRF2 may be a component of the basal  
462 mechanisms early mouse embryos employ throughout preimplantation development.

463 In contrast, KEAP1 localization was consistently detected in the cytoplasm at all stages of  
464 preimplantation embryo development, and this was as is expected since KEAP1 is the cytoplasmic  
465 binding partner and primary mediator of NRF2 proteasomal degradation (Watai et al., 2007;  
466 Canning et al., 2015). However, cytoplasmic KEAP1 localization pattern included fluorescent foci  
467 concentrated around blastomere margins. Several studies have shown that KEAP1 is associated  
468 with the actin cytoskeleton (Kang et al., 2004), including focal adhesions and adherens junctions  
469 (Velichkova & Hasson, 2003; Wu et al., 2018) and this is likely what is happening in early mouse  
470 embryos as well. Interestingly, KEAP1 immunofluorescence localization during mouse  
471 preimplantation development also included some apparent nuclear localization. Research has  
472 determined that KEAP1 engages in nucleocytoplasmic shuttling to retrieve NRF2 and target it for  
473 degradation (Nguyen et al., 2005).

474 The relative transcript levels of *Nrf2*, *Keap1*, *Gpx1*, *Cat* and *Sod1* all increased significantly  
475 during the preimplantation period, peaking at the blastocyst stage. Mouse embryos undergo major  
476 genome activations during preimplantation development that allow the embryo to shift away from  
477 maternal transcripts and towards autonomous control of the embryonic genome for development  
478 (Hamatani et al., 2004; Bell et al., 2008). *Gclc* mRNA was not significantly different across  
479 embryo stages, in contrast to our earlier study which showed an increase in expression at the  
480 blastocyst stage in a different strain of female mice (Calder et al., 2011).

481 Consistent with our previous findings, (Yousif et al., 2020), we demonstrated that treatment with  
482 100  $\mu$ M PA impairs mouse preimplantation development to the blastocyst stage, while co-  
483 treatment with 100  $\mu$ M OA rescues blastocyst development frequencies. The two non-esterified  
484 fatty acids, palmitic acid (PA) and oleic acid (OA), are of particular interest because they are the  
485 most abundant FFAs in plasma circulation and in the reproductive tract (Abdelmagid et al., 2015;  
486 Jungheim et al., 2011). Profiling of human follicular fluid has determined that PA and OA occupy  
487 approximately 27% and 31% of fatty acid content, respectively (Jungheim et al., 2011). PA is a  
488 16-carbon saturated fatty acid (16:0), and OA is an 18-carbon monounsaturated fatty acid (18:1)  
489 (Palomer et al., 2018). PA and OA are present at serum concentrations of approximately 100 $\mu$ M

490 in healthy BMI individuals, but serum levels can be elevated to anywhere between 200–400 $\mu$ M in  
491 obese individuals (Chen et al., 2010; Colvin et al., 2017; Villa et al., 2009). Therefore, treatment  
492 with concentrations of 100  $\mu$ M PA and OA are consistent with serum levels found in healthy  
493 pregnant women, but lower than the typical range found in obese or preeclamptic individuals  
494 (Chen et al., 2010; Villa et al., 2009). Few studies have quantified FFA levels within the  
495 mammalian reproductive tract, but we have reported (Yousif *et al.* 2020) reported that female CD-  
496 1 mice fed a low-fat diet maintain 400  $\mu$ M PA and 44  $\mu$ M OA concentrations in the oviduct. Most  
497 PA-treated embryos arrest at the 4- to 8-cell stages, while this does not occur in any other treatment  
498 group.

499 Little is known about the effects of PA and OA on the NRF2/KEAP1 signalling pathway  
500 during this developmental period. NRF2 immunofluorescence was consistently localized in the  
501 nuclei of blastomeres from PA, OA, and PA+OA groups after 18, 24 and 48 hours of *in vitro*  
502 treatment. The lack of significant differences between NRF2-positive nuclei in control, OA, and  
503 PA+OA groups suggests two things: first, that OA likely does not affect NRF2 activation, and  
504 second, that co-treatment with OA can rescue the impact of PA alone on NRF2 nuclear  
505 localization. NRF2 localization outcomes at the 24-hour time-point revealed no differences  
506 observed between treatment groups. Interestingly, the frequency of NRF2-positive nuclei was  
507 lowest in PA-treated embryos after 18 and 48 hours. In contrast, oxidative stress upregulated  
508 nuclear NRF2 in the bovine blastocyst (Amin et al., 2014). If PA induces stress, then one would  
509 expect nuclear NRF2 would increase, and antioxidant expression would be stimulated in response.  
510 We have previously observed that PA upregulates ER stress pathway transcripts in embryos  
511 (Yousif et al., 2020), and PERK activation phosphorylates NRF2 and increases its translocation  
512 into the nucleus in other systems (Cullinan et al., 2003). Paradoxically, PA treatment resulted in  
513 decreased nuclear NRF2 staining in one study (Fratantonio et al., 2015). Obesity and high fat diets  
514 may also decrease nuclear NRF2 and antioxidant expression (Collins et al., 2009; Elrashidy et al,  
515 2020; Balasubramanian et al., 2020). NRF2 activation is suggested as a treatment for the oxidative  
516 stress and inflammation of obesity and metabolic disorders (Elrashidy et al, 2020; Zhu et al., 2020).  
517 Increasing NRF2 expression in PA-treated podocytes reduced oxidative and ER stress as well as  
518 increased antioxidant expression and viability (Kang et al., 2021). Results from the current

519 experiments suggest that despite associated stress, PA treatment prevents preimplantation embryos  
520 from properly localizing NRF2 to the nuclear compartment.

521 KEAP1 immunofluorescence was localized in the cytoplasm of blastomeres from PA, OA,  
522 and PA+OA treated embryos at all time points. The frequency of cytoplasmic KEAP1 was high in  
523 all groups after 18 and 24 hours, consistent with KEAP1 localization studies from other tissues  
524 (Cullinan et al., 2003). After 48 hours, the frequency of cytoplasmic KEAP1 was significantly  
525 lower in OA-treated embryos compared with the other treatments. In all time points, KEAP1 also  
526 showed occasional nuclear localization, likely performing nucleocytoplasmic shuttling as  
527 previously discussed (Nguyen et al., 2005).

528 Overproduction of ROS during embryo development may result from inadequate  
529 production of antioxidants or from exposure to *in vitro* culture stresses such as high oxygen, pH,  
530 light, and temperature (Lin & Wang, 2021). *Nrf2* mRNA was upregulated by oxidative stress in  
531 the bovine embryo (Amin et al., 2014). *Sod1* mRNA was increased at the blastocyst stage when  
532 *Nrf2* mRNA and nuclear localization of the protein increased (Amin et al., 2014). *Gclc* mRNA  
533 was increased in mouse embryos cultured in high oxygen or suboptimal medium (Calder et al.,  
534 2011). However, in the current study, antioxidant mRNA expression did not increase after  
535 exposure to PA, which increased expression of the ER stress pathway members (Yousif et al.,  
536 2020). Similarly, obesity and unhealthy metabolic state was associated with ER stress but lower  
537 SOD, Catalase and GSH activity (Banuls et al., 2017; Gao et al., 2018). Zygotes from mice fed a  
538 high fat diet had higher ROS and lower glutathione content (Igosheva et al., 2010). The embryo  
539 may not respond appropriately to the stress of PA exposure, as NRF2 is retained within the  
540 cytoplasm rather than being transported to the nucleus where it may induce expression of  
541 antioxidant genes. Only embryos that developed past the 4-cell stage were used for qRT-PCR,  
542 however PA-treated embryos that did not progress past this stage may not have been able to mount  
543 an optimal antioxidant response.

544 This study advances our investigation into defining the differential effects of PA and OA  
545 on mouse preimplantation embryo development by examining the NRF2/KEAP1 pathway. Given  
546 the vulnerability of preimplantation embryo development, PA treatment at the levels investigated  
547 here may have stretched the adaptive mechanisms of the developing NRF2/KEAP1 pathway,

548 resulting in impaired preimplantation development. All studies were conducted *in vitro*, but studies  
549 on cultured early embryos remain important for eventual optimization of Assisted Reproductive  
550 Technologies (ARTs) such as elective single embryo transfer (eSET) where culture is critical to  
551 produce competent blastocysts for embryo transfer, implantation, and pregnancy.

## 552 **4. Experimental Procedures**

### 553 **4.1 Animal ethics approval**

554 All experiments used CD-1 mice sourced from Charles River Laboratories (Saint-Constant,  
555 QC). Mice were handled in accordance with the Canadian Council on Animal Care, as well as  
556 complying with Animal Care and Use Policies at Western University. Experiments are registered  
557 to Protocol #2018-075 under Dr. Andrew J. Watson. Mice were housed in conventional housing  
558 with a 12- hour light/dark cycle and access to food ad libitum (low fat diet).

### 559 **4.2 Mouse superovulation protocol**

560 Female CD-1 mice (4–6 weeks old) were super-ovulated by intraperitoneal (i.p.) injections  
561 of 5.0 international units (IU) of pregnant mare’s serum gonadotropin (PMSG, Merck Animal  
562 Health, Canada) to stimulate follicular growth. 48 hours later, the same females received i.p.  
563 injections of 5.0 IU of human chorionic gonadotropin (hCG, Merck Animal Health, Canada) to  
564 stimulate increased ovulation. After hCG injections, female mice were placed in individual cages  
565 with male CD-1 mice overnight for natural mating. For all experiments, injections were performed  
566 between 10 am and noon. The morning following mating, female mice were assessed for the  
567 presence of vaginal plugs which indicated successful mating.

### 568 **4.3 Flushing mouse embryos**

569 Only mice with seminal plugs were used to collect one-cell embryos approximately 22–24  
570 hours post-hCG. Females were sacrificed using CO<sub>2</sub> euthanasia and dissected to isolate their  
571 oviducts. Under a light microscope, the swollen portion of the oviduct was torn open to collect  
572 cumulus-oocyte complexes. These were transferred to 0.03% sterile hyaluronidase in M2 medium  
573 solution for 10–20 seconds to denude surrounding cumulus cells. One-cell embryos were collected

574 into 50  $\mu$ L of potassium simplex optimization media with amino acids (KSOM + AA, IVL04,  
575 Caisson Laboratories, Smithfield, UT), washed thrice to eliminate debris, and were then fixed for  
576 immunofluorescence or frozen at  $-80^{\circ}\text{C}$  for qPCR. For all other experiments, two-cell embryos  
577 were collected from oviducts 46 hours post-hCG, flushed under a light microscope using warmed  
578 M2 flushing medium (M7167-100, Sigma-Aldrich, Canada) in syringes with a 30g needle. After  
579 washing, embryos were distributed into 20  $\mu$ L treatment drops of KSOMaa under mineral oil  
580 (LGOL-500, LifeGlobal Group, Guilford, CT) with up to 20 embryos in each drop under an  
581 atmosphere of 5%  $\text{O}_2$ , 5%  $\text{CO}_2$ , and 90%  $\text{N}_2$ .

#### 582 **4.4 Developmental series culture and collection of preimplantation embryos**

583 Two-cell embryos were cultured in KSOMaa drops, covered by embryo-grade mineral oil,  
584 at  $37^{\circ}\text{C}$  under an atmosphere of 5%  $\text{O}_2$ , 5%  $\text{CO}_2$ , and 90%  $\text{N}_2$ . Four-cell embryos were collected  
585 at approximately 18–24 hrs of culture. Eight-cell embryos were collected at approximately 24–30  
586 hrs of culture. Morulae were collected at approximately 30–36 hrs of culture. Finally, blastocysts  
587 were collected at approximately 48 hours of culture.

#### 588 **4.5 Indirect immunofluorescence staining**

589 Embryo pools from each treatment group were fixed in 2% paraformaldehyde prepared in  
590 PBS buffer for 30 minutes then transferred to PHEM buffer for storage at  $4^{\circ}\text{C}$  according to our  
591 standard immunofluorescence protocols (Calder et al., 2011). Fixed embryos were blocked in  
592 buffer consisting of: 5% normal donkey serum (017-000-121, Jackson ImmunoResearch, West  
593 Grove, PA), 0.1% Triton X (EMD Millipore Corp., Billerica, MA), and 0.02%  $\text{NaN}_3$  (Sigma-  
594 Aldrich) in PBS. All further washes were with antibody dilution buffer consisting of: 0.5% Normal  
595 Donkey Serum, 0.05% Triton X, and 0.02%  $\text{NaN}_3$  in PBS. Embryos were incubated with either  
596 anti-NRF2 antibody (#137550, Abcam, Cambridge, MA) at a dilution of 1:100 or anti-KEAP1  
597 antibody (#PA5-99434, ThermoFisher) at a dilution of 1:100. Embryos were incubated in primary  
598 antibodies overnight at  $4^{\circ}\text{C}$ , secondary antibody incubation with donkey anti-rabbit AlexaFluor  
599 488 (711-545-152, Jackson ImmunoResearch) at a dilution of 1:400. Negative control embryos  
600 were exposed to secondary antibody only. Embryos were counterstained with rhodamine-  
601 phalloidin for staining filamentous actin at a dilution of 1:20 (P1951, Sigma) and 4',6-diamidino-

602 2-phenylindole for staining nuclei at a dilution of 1:1000 (D9542, Sigma). Finally, they were  
603 moved to glass-bottomed culture dishes (MatTek Life Sciences, Ashland, MA) containing two 5  
604  $\mu$ L drops of KSOM covered with embryo-grade mineral oil. The experiments were repeated (N=3)  
605 for each primary antibody with biologically distinct embryo pools (n=30-40 embryos measured  
606 per treatment group).

#### 607 **4.6 Confocal microscopy**

608 Embryos from all treatment groups were examined using confocal microscopy with a Zeiss  
609 LSM 800 AiryScan confocal microscope (Zeiss, Canada) which belongs to the Schulich Core  
610 Facility. Immunofluorescence images were taken using the 10x and 25x (water) objectives. Z-  
611 stacks were performed such that 10 slices of equal thickness were imaged through each embryo.  
612 On the microscope, laser master gain and intensity settings were kept constant when visualizing  
613 embryos from the same experiment.

#### 614 **4.7 RNA extraction, reverse transcription and quantitative RT-PCR (qRT-PCR) to assess** 615 **relative transcript abundance**

616 Total RNA was extracted from each embryo treatment group using a PicoPure RNA  
617 Isolation Kit (ThermoFisher Scientific). Exogenous luciferase mRNA (0.025 pg/embryo, Promega  
618 Corporation, Fitchburg, WI) was added to each sample as a reference gene for PCR and delta delta  
619 Ct analysis. DNase 1 (RNA free DNase kit, Qiagen, Toronto, ON) was used to eliminate genomic  
620 DNA from embryo samples. Embryo RNA extraction pools consisted of n=20-30 embryos for  
621 each treatment group and a minimum of N=3 replicate pools were assayed for each transcript of  
622 interest. RNA was reverse transcribed into cDNA using SensiScript Reverse Transcriptase Kit  
623 (Qiagen). cDNA was diluted to 1 embryo/ $\mu$ L using RNase-free water and stored at -20°C. Three  
624 embryo equivalents are used per gene assayed in triplicate.

625 Quantitative PCR was performed to assess the effects of culture treatments on transcripts  
626 of interest using TaqMan probes (ThermoFisher Scientific) in a 384-well plate. TaqMan primers  
627 for mouse Nrf2 (#Mm00477786\_m1 Nfe2l2), Keap1 (#Mm00497268\_m1 KEAP1), Gpx1  
628 (#Mm00656767\_g1 Gpx1), Catalase (#Mm00437992\_m1 Cat), Sod1 (#Mm01344233\_g1 Sod1)  
629 and  $\gamma$ -Glutamylcysteine ligase catalytic unit (Mm00802655\_m1 Gclc) were used for qPCR using

630 TaqMan Gene Expression Mastermix (ThermoFisher). qRT-PCR was performed using a CFX384  
631 Touch™ Real-Time PCR Detection System (BioRad, Canada). Relative transcript abundance  
632 determined using the delta-delta Ct method. qRT-PCR protocols were repeated with at least (N=3)  
633 biologically distinct embryo pools collected from unique batches of mice.

#### 634 **4.8 FFA culture treatment preparation for treatment of two-cell embryos**

635 Fatty acid-free bovine serum albumin (A6003, Sigma-Aldrich, Canada), was dissolved  
636 overnight in phosphate-buffered saline (PBS) to a final concentration of 20% BSA solution, then  
637 filter sterilized. Stock BSA solution was used for conjugation in PA (Sigma-Aldrich, Canada) or  
638 OA (Sigma-Aldrich, Canada) solution. Stock solutions were created by solubilizing PA and OA,  
639 separately, in RNase-free water and sodium hydroxide (NaOH) at 70°C, to a concentration of 20  
640 mM. Then, the stock solution was conjugated to BSA in a 2:1 molar ratio (PA or OA) and diluted  
641 with KSOMaa to make a 500 µM solution. A similar concentration of diluted BSA without added  
642 fatty acids was used for the control. Conjugated solutions were stored at 4°C for later use.

643 Treatment conditions were prepared as follows:

- 644 1) BSA in KSOM as the control (2 parts:3 parts KSOM v/v ratio)
- 645 2) 100 µM PA (1 part PA:1part BSA:3 parts KSOM v/v ratio)
- 646 3) 100 µM OA (1 part OA:1part BSA:3 parts KSOM v/v ratio)
- 647 4) 100 µM PA + 100 µM OA (1 part PA:1 part OA:3 parts KSOM v/v ratio)

#### 648 **4.9 Developmental stage assessment**

649 At the end of the culture period in fatty acids—0 to 48 hours, depending on the  
650 experiment—embryos were visually examined under a dissecting microscope at 40x to identify  
651 and record their developmental stage. Embryos were categorized as being 2-cell, 4-cell, 8-cell,  
652 morulae, or blastocysts. Cleavage stage embryos were identified based on the number of distinct  
653 blastomeres. Morulae were identified based on the presence of compacted blastomeres and the  
654 lack of a fluid-filled cavity, and blastocysts were identified as embryos with a visible fluid-filled  
655 cavity. After developmental assessment, embryos were either frozen at -80°C for mRNA transcript  
656 analyses or fixed for immunofluorescence labelling and confocal microscopy.

#### 657 **4.10 Effects of PA and OA treatment on NRF2/KEAP1 localization in preimplantation** 658 **embryos**

659 Two-cell mouse embryos were cultured in BSA control, PA, OA, or PA+OA treatments  
660 for 0 hrs, 18 hrs, 24 hrs and 48 hrs. Embryos were fixed and stained for immunofluorescence and  
661 confocal microscopy as in sections 4.5-4.6 above. Immunofluorescence images from each  
662 experiment were evaluated using FIJI (ImageJ) software. Employing Rhodamine Phalloidin and  
663 DAPI staining, the total number of cells in each embryo were counted. For NRF2 localization  
664 experiments, the number of cells with NRF2-fluorescent nuclei were counted for each embryo,  
665 defined as co-localization between the NRF2 and DAPI channels. Cell counts were used to  
666 calculate the mean percentage of NRF2-positive nuclei for each treatment. For KEAP1 localization  
667 experiments, the number of cells with KEAP1 fluorescence were counted for each embryo, defined  
668 as visual presence of KEAP1 staining inside cell boundaries. Cell counts were used to calculate  
669 the mean percentage of KEAP1-positive cells for each treatment. Cell counting for all experiments  
670 was performed using Z-stack images.

#### 671 **4.11 Effects of PA and OA treatment on Relative Transcript Abundance**

672 After 48 hours of culture from the 2-cell stage, embryos of control, PA, OA and PA+OA  
673 were collected and frozen at -80°C. RNA extraction was performed as in section 4.7 above and  
674 qPCR was performed to assess the effects of culture treatments on *Nrf2*, *Keap1*, *Gpx1*, *Cat*, *Sod1*  
675 and *Gclc* mRNAs.

#### 676 **4.12 Statistical Analyses**

677 GraphPad Prism 9 was used to perform all statistical analyses. For immunofluorescence  
678 imaging studies, a biological replicate was defined as a single embryo within a treatment group.  
679 For developmental assessments and qRT-PCR gene expression analyses, a biological replicate was  
680 defined as an embryo pool from a distinct group of mice. All statistical tests employed a  
681 significance threshold of  $p < 0.05$ . Within each treatment group, developmental stage frequency  
682 was compared using one-way analysis of variance (ANOVA) with Tukey's post-hoc test for  
683 multiple comparisons. Blastocyst frequencies were compared between treatment groups using one-  
684 way ANOVA with Tukey's post-hoc test. For immunofluorescence image analysis, percentage of

685 NRF2-positive nuclei were compared between treatment groups using one-way ANOVA with  
686 Tukey's post-hoc test. Similarly, percentage of KEAP1-positive cells were compared between  
687 treatment groups using one-way ANOVA with Tukey's post-hoc test. Relative mRNA abundance  
688 was determined from Ct values using the delta-delta Ct method. Quantification of relative  
689 transcript abundance for each gene was followed by one-way ANOVA and Tukey's post-hoc test  
690 to compare between treatment groups. Where data did not pass tests for normality and equal  
691 variance, a non-parametric Kruskal-Wallis test was performed with Dunn's multiple comparison  
692 tests to detect differences among stages or treatments.

### 693 **Acknowledgements:**

694 We are grateful to Zuleika Leung for assistance with embryo collections and technical  
695 assistance. This work was supported by a project grant from the Canadian Institutes of Health  
696 Research (CIHR) Canada to DHB, BAR and AJW.

697

### 698 **Declaration of Competing Interests:**

699 The authors state that they have no competing interests to declare.

700

### 701 **Author Contributions:**

702 GD conducted all the experiments, assisted with experimental design, conducted initial  
703 data analysis, and drafted the manuscript. MC assisted with embryo collection, RT-PCR data  
704 collection, manuscript writing and data analysis; DHB and BaR assisted with study design, project  
705 funding acquisition and editing the manuscript. AJW was principal investigator on the study,  
706 oversaw study design, manuscript production and lead project funding acquisition.

707

- 709 1. Aardema, H., Vos, P. L. A. M., Lolicato, F., Roelen, B. A. J., Knijn, H. M., Vaandrager,  
710 A. B., Helms, B. J., & Gadella, B. M. (2011). Oleic acid prevents detrimental effects of  
711 saturated fatty acids on bovine oocyte developmental competence. *Biology of*  
712 *Reproduction*, 85(1), 62–69. doi: 10.1095/biolreprod.110.088815
- 713 2. Abdelmagid, S. A., Clarke, S. E., Nielsen, D. E., Badawi, A., El-Soheby, A., Mutch, D.  
714 M., & Ma, D. W. L. (2015). Comprehensive profiling of plasma fatty acid concentrations  
715 in young healthy Canadian adults. *PLoS ONE*, 10(2), e0116195. doi:  
716 10.1371/journal.pone.0116195
- 717 3. Abe, H., Yamashita, S., Itoh, T., Satoh, T., Hoshi, H. (1999). Ultrastructure of bovine  
718 embryos developed from in vitro-matured and -fertilized oocytes: comparative  
719 morphological evaluation of embryos cultured either in serum-free medium or in serum-  
720 supplemented medium. *Molecular Reproduction and Development* 53(3):325-35. doi:  
721 10.1002/(SICI)1098-2795(199907)53:3<325::AID-MRD8>3.0.CO;2-T.
- 722 4. Abraham, T., Pin, C.L., Watson, A.J. (2012). Embryo collection induces transient  
723 activation of the XBP1 arm of the ER stress response while embryo vitrification does not.  
724 *Molecular Human Reproduction*, 18(5), 229-242. doi: 10.1093/molehr/gar076.
- 725 5. Amin, A., Gad, A., Salilew-Wondim, D., Prastowo, S., Held, E., Hoelker, M., Rings, F.,  
726 Tholen, E., Neuhoff, C., Looft, C., Schellander, K., & Tesfaye, D. (2014). Bovine  
727 embryo survival under oxidative-stress conditions is associated with activity of the  
728 NRF2-mediated oxidative-stress-response pathway. *Molecular Reproduction and*  
729 *Development*, 81(6), 497-513. doi: 10.1002/mrd.22316
- 730 6. ASRM (2015). Obesity and reproduction: a committee opinion. *Fertility and*  
731 *Sterility* 104(5), 1116–1126. doi: 10.1016/j.fertnstert.2015.08.018
- 732 7. Balasubramanian, P., Asirvatham-Jeyaraj, N., Monteiro, R., Sivasubramanian, M.K.,  
733 Hall, D., & Subramanian, M. (2020). Obesity-induced sympathoexcitation is associated  
734 with Nrf2 dysfunction in the rostral ventrolateral medulla. *American Journal of*  
735 *Physiology: Regulatory, Integrative and Comparative Physiology*, 318(2), R435-R444.  
736 doi: 10.1152/ajpregu.00206.2019
- 737 8. Banuls, C., Rovira-Llopis, S., Lopez-Domenech, S., Diaz-Morales, N., Blas-Garcia, A.,  
738 Veses, S., Morillas, C., Victor, V.M., Rocha, M. & Hernandez-Mijares, A. (2017).  
739 Oxidative and endoplasmic reticulum stress is impaired in leukocytes from metabolically  
740 unhealthy vs healthy obese individuals. *International Journal of Obesity*, 41(10), 1556-  
741 1563. doi: 10.1038/ijo.2017.147.
- 742 9. Bell, C.E., Calder, M.D., & Watson, A.J. (2008). Genomic RNA profiling and the  
743 programme controlling preimplantation mammalian development. *Molecular Human*  
744 *Reproduction* 14(12), 691-701. doi: 10.1093/molehr/gan063.
- 745 10. Boivin, J., Bunting, L., Collins, J.A., & Nygren, K.G. (2007). International estimates of  
746 infertility prevalence and treatment-seeking: potential need and demand for infertility  
747 medical care. *Human Reproduction* 22(6), 1506-1512. doi: 10.1093/humrep/dem046.
- 748 11. Broughton, D. E., & Moley, K. H. (2017). Obesity and female infertility: potential  
749 mediators of obesity’s impact. *Fertility and Sterility* 107(4), 840–847. doi:  
750 10.1016/j.fertnstert.2017.01.017

- 751 12. Calder, M.D, Watson, P.H., & Watson, A.J. (2011). Culture medium, gas atmosphere and  
752 MAPK inhibition affect regulation of RNA-binding targets during mouse preimplantation  
753 development. *Reproduction* 142, 689-698. doi: 10.1530/REP-11-0082
- 754 13. Canning, P., Sorrell, F. J., & Bullock, A. N. (2015). Structural basis of KEAP1  
755 interactions with NRF2. *Free Radical Biology and Medicine*, 88(B), 101–107. doi:  
756 10.1016/j.freeradbiomed.2015.05.034
- 757 14. Chambers, G.M., Dyer, S., Zegers-Hochschild, F., de Mouzon, J., Ishihara, O., Banker,  
758 M., Mansour, R., Kupka, M. S., Adamson, G.D. (2021). International committee for  
759 monitoring assisted reproductive technologies world report: assisted reproductive  
760 technology, 2014. *Human Reproduction*, 36(11), 2921–2934. doi:  
761 10.1093/humrep/deab198.
- 762 15. Chazaud, C., & Yamanaka, Y. (2016). Lineage specification in the mouse  
763 preimplantation embryo. *Development*, 143(7), 1063–1074. doi: 10.1242/dev.128314
- 764 16. Chen, X., Scholl, T. O., Leskiw, M., Savaille, J., & Stein, T. P. (2010). Differences in  
765 maternal circulating fatty acid composition and dietary fat intake in women with  
766 gestational diabetes mellitus or mild gestational hyperglycemia. *Diabetes Care*, 33(9),  
767 2049–2054. doi: 10.2337/dc10-0693
- 768 17. Collins, A.R., Lyon, C.J., Xia, X., Liu, J.Z., Tangirala, R.K., Yin, F., Boyadjian, R.,  
769 Bikineyeva, A., Pratico, D., Harrison, D.G., & Hsueh, W.A. (2009). Age-accelerated  
770 atherosclerosis correlates with failure to upregulate antioxidant genes. *Circulation*  
771 *Research*, 104(6), e42-e54. doi: 10.1161/CIRCRESAHA.108.188771.
- 772 18. Cuadrado, A., Rojo, A.I., Wells, G., Hayes, J.D., Cousin, S.P., Rumsey, W.L., Attucks,  
773 O.C., Franklin, S., Levonen, A-L., Kensler, T.W. & Dinkova-Kostova, A.T. (2019).  
774 Therapeutic targeting of the Nrf2 and Keap1 partnership in chronic diseases. *Nature*  
775 *Reviews Drug Discovery*, 18(4), 295-317. doi: 10.1038/s41573-018-0008-x.
- 776 19. Cullinan, S.B., Zhang, D., Hannink, M., Arvisais, E., Kaufman, R.J., & Diehl, J.A.  
777 (2003). NRF2 is a direct PERK substrate and effector of PERK-dependent cell survival.  
778 *Molecular and Cellular Biology* 23(20), 7198-7209. doi: 10.1128/MCB.23.20.7198-  
779 7209.2003.
- 780 20. Cullinan, S. B., Gordan, J. D., Jin, J., Harper, J. W., & Diehl, J. A. (2004). The KEAP1-  
781 BTB Protein Is an Adaptor That Bridges NRF2 to a Cul3-Based E3 Ligase: Oxidative  
782 Stress Sensing by a Cul3-KEAP1 Ligase. *Molecular and Cellular Biology*, 24(19), 8477–  
783 8486. doi: 10.1128/mcb.24.19.8477-8486.2004
- 784 21. Dong, J., Sulik, K.K., & Chen, S-Y. (2008). Nrf2-mediated transcriptional induction of  
785 antioxidant response in mouse embryos exposed to ethanol *in vivo*: implications for the  
786 prevention of fetal alcohol spectrum disorders. *Antioxidants and Redox Signaling*,  
787 10(12), 2023-2033. doi: 10.1089/ars.2007.2019
- 788 22. Elrashidy, R.A. (2020). Dysregulation of nuclear factor erythroid 2-related factor w  
789 signaling and activation of fibrogenic pathways in hearts of high fat diet-fed rats.  
790 *Molecular Biology Reports*, 47(4), 2821-2834. doi: 10.1007/s11033-020-05360-3.
- 791 23. Favetta, L. A., St. John, E. J., King, W. A., & Betts, D. H. (2007). High levels of p66shc  
792 and intracellular ROS in permanently arrested early embryos. *Free Radical Biology and*  
793 *Medicine*, 42(8), 1201–1210. doi: 10.1016/j.freeradbiomed.2007.01.018  
794  
795

- 796 24. Fratantonio, D., Speciale, A., Ferrari, D., Cristani, M., Saija, A., & Cimino, F. (2015).  
797 Palmitate-induced endothelial dysfunction is attenuated by cyanidin-3-O-glucoside  
798 through modulation of Nrf2/Bach1 and NFκB pathways. *Toxicology Letters*, 239(3), 152-  
799 160. doi: 10.1016/j.toxlet.2015.09.020.
- 800 25. Furukawa, S., Fujita, T., Shimabukoro, M., Iwaki, M., Yamada, Y., Nakajima, Y.,  
801 Nakayama, O., Makishima, M., Matsuda, M., & Shimomura, I. (2004). Increased  
802 oxidative stress in obesity and its impact on metabolic syndrome. *Journal of Clinical*  
803 *Investigation* 114(12), 1752-1761. doi: 10.1172/JCI21625.
- 804 26. Gao, W., Du, X., Lei, L., Wang, H., Zhang, M., Wang, Z., Li, X., Liu, G., & Li, X.  
805 (2018). NEFA-induced ROS impaired insulin signalling through the JNK and p38MAPK  
806 pathways in non-alcoholic steatohepatitis. *Journal of Cellular and Molecular Medicine*,  
807 22(7), 3408–3422. doi: 10.1111/jcmm.13617
- 808 27. Guerin, P., El Mouatassim, S., & Menezo, Y. (2001). Oxidative stress and protection  
809 against reactive oxygen species in the pre-implantation embryo and its surroundings.  
810 *Human Reproduction Update*, 7(2), 175-189. doi: 10.1093/humupd/7.2.175.
- 811 28. Hamatani, T., Carter, M. G., Sharov, A. A., & Ko, M. S. H. (2004). Dynamics of Global  
812 Gene Expression Changes during Mouse Preimplantation Development. *Developmental*  
813 *Cell*, 6(1), 117–131. doi: 10.1016/s1534-5807(03)00373-3.
- 814 29. Harvey, M.B., Arcellana-Panlilio, M.Y., Zhang, X., Schultz, G.A., & Watson, A.J.  
815 (1995). Expression of genes encoding antioxidant enzymes in preimplantation mouse and  
816 cow embryos and primary bovine oviduct cultures employed for embryo co-culture.  
817 *Biology of Reproduction* 53(3), 532-540. doi: 10.1095/biolreprod53.3.532.
- 818 30. Herbemont, C., Labrosse, J., Bennani-Smires, B., Cedrin-Durnerin, I., Peigne, M.,  
819 Sermondade, N., Sarandi, S., Vivot, A., Vicaut, E., Talib, Z., Grynberg, M., & Sifer, C.  
820 (2021). Impact of oxygen tension according to embryo stage of development: a  
821 prospective randomized study. *Science Reports* 11(1), 22313. doi: 10.1038/s41598-021-  
822 01488-9.
- 823 31. Huang, Y., Li, W., Su, Z-Y., & Kong, A-N. T. (2015). The complexity of the NRF2  
824 pathway: beyond the antioxidant response. *Journal of Nutritional Biochemistry*, 26(12),  
825 1401–1413. doi: 10.1016/j.jnutbio.2015.08.001
- 826 32. Igosheva, N., Abramov, A.Y., Poston, L., Eckert, J.J., Fleming, T.P., Duchon, M.R.,  
827 McConnell, J. (2010). Maternal diet-induced obesity alters mitochondrial activity and  
828 redox status in mouse oocytes and zygotes. *PLoS One*, 5(4), e10074.  
829 doi.org/10.1371/journal.pone.0010074
- 830 33. Jaiswal, A.K. (2004). Nrf2 signaling in coordinated activation of antioxidant gene  
831 expression. *Free Radical Biology and Medicine*, 36(10), 1199-1207. doi:  
832 10.1016/j.freeradbiomed.2004.02.074.
- 833 34. Jungheim, E. S., Macones, G. A., Odem, R. R., Patterson, B. W., Lanzendorf, S. E.,  
834 Ratts, V. S., & Moley, K. H. (2011). Associations between free fatty acids, cumulus  
835 oocyte complex morphology and ovarian function during in vitro fertilization. *Fertility*  
836 *and Sterility*, 95(6), 1970–1974. doi: 10.1016/j.fertnstert.2011.01.154
- 837 35. Kang, J.S., Son, S.S., Lee, J-H., Lee, S-W., Jeong, A.R., Lee, E.S., Cha, S-K., Chung,  
838 C.H., & Lee, E-Y. (2021). Protective effects of klotho on palmitate-induced podocyte  
839 injury in diabetic nephropathy. *PLoS One*, 16(4), e0250666. doi:  
840 10.1371/journal.pone.0250666.

- 841 36. Kang, M-I., Kobayashi, A., Wakabayashi, N., Kim, S-G., & Yamamoto, M. (2004).  
842 Scaffolding of Keap1 to the actin cytoskeleton controls the function of Nrf2 as key  
843 regulator of cytoprotective phase 2 genes. *Proceedings of the National Academy of*  
844 *Sciences USA*, 101(7), 2046-2051. doi: 10.1073/pnas.0308347100.
- 845 37. Kensler, T.W., Wakabayashi, W., & Biswal, S. (2007). Cell survival responses to  
846 environmental stresses via the Keap1-Nrf2-ARE pathway. *Annual Reviews in*  
847 *Pharmacology and Toxicology*, 47:89-116. doi:  
848 10.1146/annurev.pharmtox.46.120604.141046.
- 849 38. Kim, E. H., Kim, G. A., Taweechaipaisankul, A., Lee, S. H., Qasim, M., Ahn, C., & Lee,  
850 B. C. (2019). Melatonin enhances porcine embryo development via the NRF2/ARE  
851 signaling pathway. *Journal of Molecular Endocrinology*, 63(3), 175–185. doi:  
852 10.1530/JME-19-0093
- 853 39. Kikuchi, K., Ekwel, H., Tienthai, P., Noguchi, J., Kaneko, H., Rodriguez-Martinez, H.  
854 (2002). Morphological features of lipid droplet transition during porcine oocytes  
855 fertilisation and early embryonic development to blastocyst in vivo and in vitro. *Zygote*,  
856 10(4):355-66. doi: 10.1017/s0967199402004100.
- 857 40. Lee, J.M., Calkins, M.J., Chan, K., Kan, Y.W., & Johnson, J.A. (2003). Identification of  
858 NF-E2-related factor-2-dependent genes conferring protection against oxidative stress in  
859 primary cortical astrocytes using oligonucleotide microarray analysis. *Journal of*  
860 *Biological Chemistry*, 278(14), 12029-12038. doi: 10.1074/jbc.M211558200.
- 861 41. Leroy, J. L. M. R., Vanholder, T., Mateusen, B., Christophe, A., Opsomer, G., de Kruif,  
862 A., Genicot, G., & Van Soom, A. (2005). Non-esterified fatty acids in follicular fluid of  
863 dairy cows and their effect on developmental capacity of bovine oocytes in vitro.  
864 *Reproduction*, 130(4), 485–495. doi: 10.1530/rep.1.00735
- 865 42. Lin, J., & Wang, L. (2021). Oxidative stress in oocyte and embryo development:  
866 implications for in vitro systems. *Antioxidants and Redox Signaling* 34 (17), 1394-1406.  
867 doi: 10.1089/ars.2020.8209
- 868 43. Lin, T., Lee, J. E., Kang, J. W., Shin, H. Y., Lee, J. B., & Jin, D. I. (2019). Endoplasmic  
869 reticulum (ER) stress and unfolded protein response (UPR) in mammalian oocyte  
870 maturation and preimplantation embryo development. *International Journal of Molecular*  
871 *Sciences* 20 (2), 409. doi: 10.3390/ijms20020409
- 872 44. Lin, Y., Sui, L.-C., Wu, R.-H., Ma, R.-J., Fu, H.-Y., Xu, J.-J., Qiu, X.-H., & Chen, L.  
873 (2018). NRF2 inhibition affects cell cycle progression during early mouse embryo  
874 development. *Journal of Reproduction and Development*, 64(1), 49–55. doi:  
875 10.1262/jrd.2017-042.
- 876 45. Liu, Y., Lu, F., Kang, L., Wang, Z., & Wang, Y. (2017). Pirfenidone attenuates  
877 bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium.  
878 *BMC Pulmonary Medicine*, 17(1), 63. doi: 10.1186/s12890-017-0405-7.
- 879 46. Meintjes, M., Chantilis, S.J., Douglas, J.D., Rodriguez, A.J., Guerami, A.R., Bookout,  
880 D.M., Barnett, B.D., Madden, J.D. (2009). A controlled randomized trial evaluating the  
881 effect of lowered incubator oxygen tension on live births in a predominantly blastocyst  
882 transfer program. *Human Reproduction*, 24(2), 300-307. doi: 10.1093/humrep/den368
- 883 47. Mota, M., Banini, B. A., Cazanave, S. C., & Sanyal, A. J. (2016). Molecular mechanisms  
884 of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease. *Metabolism*, 65(8),  
885 1049–1061. doi: 10.1016/j.metabol.2016.02.014

- 886 48. Nguyen, T., Sherratt, P. J., Nioi, P., Yang, C. S., & Pickett, C. B. (2005). NRF2 controls  
887 constitutive and inducible expression of ARE-driven genes through a dynamic pathway  
888 involving nucleocytoplasmic shuttling by KEAP1. *Journal of Biological Chemistry*,  
889 280(37), 32485–32492. doi: 10.1074/jbc.M503074200
- 890 49. Palomer, X., Pizarro-Delgado, J., Barroso, E., & Vazquez-Carrera, M. (2018). Palmitic  
891 and Oleic Acid: The Yin and Yang of Fatty Acids in Type 2 Diabetes Mellitus. *Trends in*  
892 *Endocrinology and Metabolism*, 29(3), 178–190. doi: 10.1016/j.tem.2017.11.009
- 893 50. Rinaudo, P.F., Giritharan, G., Talbi, S., Dobson, A.T., & Schultz, R.M. (2006). Effects of  
894 oxygen tension on gene expression in preimplantation mouse embryos. *Fertility and*  
895 *Sterility* 86(4 supplement), 1252-1265. doi: 10.1016/j.fertnstert.2006.05.017.
- 896 51. Sant, K. E., Hansen, J. M., Williams, L. M., Tran, N. L., Goldstone, J. V., Stegeman, J. J.,  
897 Hahn, M. E., & Timme-Laragy, A. (2017). The role of Nrf1 and NRF2 in the regulation  
898 of glutathione and redox dynamics in the developing zebrafish embryo. *Redox Biology*,  
899 13, 207–218. doi: 10.1016/j.redox.2017.05.023
- 900 52. Sinclair, K. D., Lunn, L. A., Kwong, W. Y., Wonnacott, K., Linforth, R. S. T., &  
901 Craigon, J. (2008). Amino acid and fatty acid composition of follicular fluid as predictors  
902 of in-vitro embryo development. *Reproductive BioMedicine Online*, 16(6), 859–868. doi:  
903 10.1016/S1472-6483(10)60153-8
- 904 53. Sporn, M.B. & Liby, K.T. (2012). Nrf2 and cancer: the good, the bad and the importance  
905 of context. *Nature Reviews Cancer*, 12(8), 564-571. doi: 10.1038/nrc3278.
- 906 54. Statistics Canada (2020). Table 13-10-0373-01 Overweight and obesity based on  
907 measured body mass index, by age group and sex. doi: 10.25318/1310037301-eng
- 908 55. Sunderam, S., Kissin, D. M., Crawford, S. B., Folger, S. G., Boulet, S.L., Warner, L., &  
909 Barfield, W. D. (2018). Assisted reproductive technology surveillance - United States,  
910 2015. *MMWR Surveillance Summaries*, 67(3), 1–28. doi: 10.15585/mmwr.ss6703a1.
- 911 56. Suzuki, T., & Yamamoto, M. (2015). Molecular basis of the KEAP1-NRF2 system. *Free*  
912 *Radical Biology and Medicine* 88(Part B), 93–100. doi:  
913 10.1016/j.freeradbiomed.2015.06.006
- 914 57. Talmor, A., & Dunphy, B. (2015). Female obesity and infertility. *Best Practice and*  
915 *Research: Clinical Obstetrics and Gynaecology*, 29(4), 498–506. doi:  
916 10.1016/j.bpobgyn.2014.10.014
- 917 58. Thimmulappa, R.K., Mai, K.H., Srisuma, S., Kensler, T.W., Yamamoto, M., & Biswal, S.  
918 (2002). Identification of Nrf2-regulated genes induced by the chemopreventive agent  
919 sulforaphane by oligonucleotide microarray. *Cancer Research*, 62(18), 5196-5203.
- 920 59. Tonelli, C., Chio, I. I. C., & Tuveson, D. A. (2018). Transcriptional Regulation by NRF2.  
921 *Antioxidants and Redox Signaling*, 29(17), 1727–1745. doi: 10.1089/ars.2017.7342
- 922 60. Velichkova, M., & Hasson, T. (2003). KEAP1 in Adhesion Complexes. *Cell Mobility*  
923 *and the Cytoskeleton*, 56(2), 109-119. doi: 10.1002/cm.10138.
- 924 61. Villa, P. M., Laivuori, H., Kajantie, E., & Kaaja, R. (2009). Free fatty acid profiles in  
925 preeclampsia. *Prostaglandins Leukotrienes and Essential Fatty Acids*, 81(1), 17–21.  
926 <https://doi.org/10.1016/j.plefa.2009.05.002>
- 927 62. Wale, P.L. & Gardner, D.K. (2012). Oxygen regulates amino acid turnover and  
928 carbohydrate uptake during the preimplantation period of mouse embryo development.  
929 *Biology of Reproduction* 87(1), 24, 1-8. doi: 10.1095/biolreprod.112.100552.

- 930 63. Wamaitha, S. E., & Niakan, K. K. (2018). Human Pre-gastrulation Development. *Current*  
931 *Topics in Developmental Biology*, 128, 295–338. doi: 10.1016/B978-0-12-804252-  
932 6.00012-9
- 933 64. Watai, Y., Kobayashi, A., Nagase, H., Mizukami, M., McEvoy, J., Singer, J.D., Itoh, K.,  
934 & Yamamoto, M. (2007). Subcellular location and cytoplasmic complex status of  
935 endogenous Keap1. *Genes to Cells*, 12(10), 1163-1178. doi: 10.1111/j.1365-  
936 2443.2007.01118.x.
- 937 65. Watson, A.J., & Barcroft, L.C. (2001). Regulation of blastocyst formation. *Frontiers in*  
938 *Bioscience* 6(3), D708-730. doi: 10.2741/watson.
- 939 66. Wei, Y., Wang, D., Topczewski, F., Pagliassotti, M.J. (2006). Saturated fatty acids  
940 induce endoplasmic reticulum stress and apoptosis independently of ceramide in liver  
941 cells. *American Journal of Physiology-Endocrinology Metabolism*, 291(2), E275-281.  
942 doi: 10.1152/ajpendo.00644.2005.
- 943 67. Wu, B., Yang, S., Sun, H., Sun, T., Ji, F., Wang, Y., Xu, L., & Zhou, D. (2018). KEAP1  
944 inhibits metastatic properties of NSCLC cells by stabilizing architectures of F-actin and  
945 focal adhesions. *Molecular Cancer Research*, 16(3), 508–516. doi: 10.1158/1541-  
946 7786.MCR-17-0544
- 947 68. Yousif, Maisoon D, Calder, M. D., Du, J. T., Ruetz, K. N., Crocker, K., Urquhart, B. L.,  
948 Betts, D. H., Rafea, B. A., & Watson, A. J. (2020). Oleic Acid Counters Impaired  
949 Blastocyst Development Induced by Palmitic Acid During Mouse Preimplantation  
950 Development: Understanding Obesity-Related Declines in Fertility. *Reproductive*  
951 *Sciences*, 27(11), 2038–2051. doi: 10.1007/s43032-020-00223-5
- 952 69. Zhu, C-G., Luo, Y., Wang, H., Li, J-Y., Yang, J., Liu, Y-X., Qu, H-Q., Wang, B-L., &  
953 Zhu, M. (2020). Liraglutide ameliorates lipotoxicity-induced oxidative stress by  
954 activating the NRF2 pathway in HepG2 cells. *Hormone and Metabolic Research*, 52(7),  
955 532-539. doi: 10.1055/a-1157-0166.
- 956